rs116869525 - TSBP1-AS1 - HLA-DRA
Magnitude 4.5 · 1 study on file
Reported associations
-
Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study - Unknown journal (n.d.) · Unknown authors · PubMed 26151496
ABSTRACT: Graves' disease is the leading cause of hyperthyroidism affecting 1.0-1.6% of the population. Antithyroid drugs are the treatment cornerstone, but may cause life-threatening agranulocytosis. Here we conduct a two-stage association study on two separate subject sets (in total 42 agranulocytosis cases and 1,208 Graves' disease controls), using direct human leukocyte antigen genotyping and SNP-based genome-wide association study. We demonstrate HLA-B38:02 (Armitage trend Pcombined=6.75 × 10−32) and HLA-DRB108:03 (Pcombined=1.83 × 10−9) as independent susceptibility loci. The genome-wide association study identifies the same signals. Estimated odds ratios for these two loci comparing effective allele carriers to non-carriers are 21.48 (95% confidence interval=11.13-41.48)
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Drug interactions
-
thionamide antithyroid drugs if Graves' disease diagnosed High
rs116869525 is in LD with HLA-DRB1*08:03, conferring 4.16-fold increased risk of life-threatening agranulocytosis when taking thionamides.
Discuss alternatives (beta-blockers, radioactive iodine, surgery) with endocrinologist before starting thionamides.